Cholangiocarcinoma laboratory findings: Difference between revisions
(Created page with "{{Cholangiocarcinoma}} {{CMG}} ==Overview== ==Blood tests== There are no specific blood tests that can diagnose cholangiocarcinoma by themselves. Serum levels of [[carci...") |
|||
| Line 3: | Line 3: | ||
==Overview== | ==Overview== | ||
[[Liver function tests|Blood tests of liver function]] in patients with cholangiocarcinoma often reveal a so-called "obstructive picture", with elevated [[bilirubin]], [[alkaline phosphatase]], and [[gamma glutamyl transferase]] levels and relatively normal [[transaminase]] levels. Such laboratory findings suggest obstruction of the bile ducts, rather than [[inflammation]] or infection of the liver, as the primary cause of the jaundice.<ref name="feldman">Feldman, pp. 1493–1496.</ref> | |||
==Blood tests== | ==Blood tests== | ||
Revision as of 12:27, 14 January 2012
|
Cholangiocarcinoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cholangiocarcinoma laboratory findings On the Web |
|
American Roentgen Ray Society Images of Cholangiocarcinoma laboratory findings |
|
Risk calculators and risk factors for Cholangiocarcinoma laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Blood tests of liver function in patients with cholangiocarcinoma often reveal a so-called "obstructive picture", with elevated bilirubin, alkaline phosphatase, and gamma glutamyl transferase levels and relatively normal transaminase levels. Such laboratory findings suggest obstruction of the bile ducts, rather than inflammation or infection of the liver, as the primary cause of the jaundice.[1]
Blood tests
There are no specific blood tests that can diagnose cholangiocarcinoma by themselves. Serum levels of carcinoembryonic antigen (CEA) and CA19-9 are often elevated, but are not sensitive or specific enough to be used as a general screening tool. However, they may be useful in conjunction with imaging methods in supporting a suspected diagnosis of cholangiocarcinoma.[2]
References
- ↑ Feldman, pp. 1493–1496.
- ↑ Studies of the performance of serum markers for cholangiocarcinoma (such as carcinoembryonic antigen and CA19-9) in patients with and without primary sclerosing cholangitis include the following:
- Nehls O, Gregor M, Klump B (2004). "Serum and bile markers for cholangiocarcinoma". Semin Liver Dis. 24 (2): 139–54. PMID 15192787.
- Siqueira E, Schoen R, Silverman W, Martin J, Rabinovitz M, Weissfeld J, Abu-Elmaagd K, Madariaga J, Slivka A, Martini J (2002). "Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis". Gastrointest Endosc. 56 (1): 40–7. PMID 12085033.
- Levy C, Lymp J, Angulo P, Gores G, Larusso N, Lindor K (2005). "The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis". Dig Dis Sci. 50 (9): 1734–40. PMID 16133981.
- Patel A, Harnois D, Klee G, LaRusso N, Gores G (2000). "The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis". Am J Gastroenterol. 95 (1): 204–7. PMID 10638584.